First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis

Introduction: We performed a meta-analysis in order to analyze and quantify the effect on survival of starting therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients with anti-EGFR agents or bevacizumab. Patients and Methods: Randomized, phase II or III, clinical trials reporting...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottaiano, Alessandro, De Stefano, Alfonso, Capozzi, Monica, Nappi, Anna, De Divitiis, Chiara, Romano, Carmela, Silvestro, Lucrezia, Cassata, Antonino, Casaretti, Rossana, Tafuto, Salvatore, Caraglia, Michele, Berretta, Massimiliano, Nasti, Guglielmo, Avallone, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943532/
https://www.ncbi.nlm.nih.gov/pubmed/29773991
http://dx.doi.org/10.3389/fphar.2018.00441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943532/
https://www.ncbi.nlm.nih.gov/pubmed/29773991
http://dx.doi.org/10.3389/fphar.2018.00441

Ejemplares similares